Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hyperinsulinemic hypoglycemia in which the cause of the disease is a mutation in the HADH gene.
Features include always present findings: Feeding difficulties and Hyperinsulinemic hypoglycemia; and common findings: Hypoglycemic seizures and Low muscle tone (hypotonia). 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Hypoglycemic seizures, Intellectual disability |
Digestive system | 1 | Feeding difficulties |
Muscles | 1 | Low muscle tone (hypotonia) |
Age of onset: newborn period.
HADH encodes hydroxyacyl-CoA dehydrogenase (314 aa). Mitochondrial fatty acid beta-oxidation enzyme that catalyzes the third step of the beta-oxidation cycle for medium and short-chain 3-hydroxy fatty acyl-CoAs (C4 to C10). Highest expression in Muscle Skeletal (55.6 TPM) and Adipose Visceral Omentum (50.9 TPM).
Hyperinsulinemic hypoglycemia, familial, 4 is associated with mutations in the HADH gene on chromosome 4.
The HADH protein participates in MLCL is acylated to CL by HADH (IM), (S)-3-Hydroxydodecanoyl-CoA+NAD = 3-Oxododecanoyl-CoA+NADH+H, and (S)-Hydroxydecanoyl-CoA+NAD = 3-Oxodecanoyl-CoA+NADH+H pathways.
HADH is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for HADH is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hyperinsulinemic hypoglycemia, familial, 4.
12 publications have been identified in PubMed for hyperinsulinemic hypoglycemia, familial, 4. Research spans Case Report / Case Series (50%), Epidemiology / Natural History (33%), and Review / Meta-Analysis (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 50% |
Disease patterns and progression | 4 | 33% |
Research summaries | 1 | 8% |
Laboratory research | 1 | 8% |
Widmer A (2026). [PMID: 40705962](https://pubmed.ncbi.nlm.nih.gov/40705962/). *The Journal of clinical endocrinology and metabolism*. [Case Report / Case Series]
Takasugi Y (2026). [PMID: 42147507](https://pubmed.ncbi.nlm.nih.gov/42147507/). *Cureus*. [Case Report / Case Series]
Khan MA (2026). [PMID: 42220696](https://pubmed.ncbi.nlm.nih.gov/42220696/). *Cureus*. [Case Report / Case Series]
Buhur Pirimoglu M (2025). [PMID: 40715678](https://pubmed.ncbi.nlm.nih.gov/40715678/). *Irish journal of medical science*. [Case Report / Case Series]
Velde CD (2025). [PMID: 38963811](https://pubmed.ncbi.nlm.nih.gov/38963811/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Kaminska D (2025). [PMID: 40425033](https://pubmed.ncbi.nlm.nih.gov/40425033/). *Obesity reviews : an official journal of the International Association for the Study of Obesity*. [Review / Meta-Analysis]
Maly J (2025). [PMID: 40287849](https://pubmed.ncbi.nlm.nih.gov/40287849/). *Journal of pediatric endocrinology & metabolism : JPEM*. [Epidemiology / Natural History]
Kattamanchi D (2024). [PMID: 39266029](https://pubmed.ncbi.nlm.nih.gov/39266029/). *BMJ case reports*. [Case Report / Case Series]
Butnariu LI (2024). [PMID: 38791571](https://pubmed.ncbi.nlm.nih.gov/38791571/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Sozaeva LS (2024). [PMID: 39659388](https://pubmed.ncbi.nlm.nih.gov/39659388/). *JCEM case reports*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning hyperinsulinemic hypoglycemia, familial, 4
Updated Mar 24, 2026
Rezolute received supportive feedback from the FDA regarding its hypoglycemia drug, ersodetug, despite missing the Phase 3 primary endpoint. The FDA recognized behavioral factors as a potential confounding issue, indicating a possible path forward for the drug's development.
A rare case report highlights the association of linezolid with a triad of acute pancreatitis, lactic acidosis, and hypoglycemia. This literature review provides insights into the potential adverse effects of linezolid, emphasizing the need for awareness among healthcare providers.
Rezolute is conducting two Phase 3 trials for its first-in-class monoclonal antibody therapy, ersodetug, aimed at treating hypoglycemia due to hyperinsulinism. The study highlights challenges in demonstrating therapeutic benefit in ultra-rare diseases, emphasizing the need for alternative approaches beyond traditional RCTs.